{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T01:52:32Z","timestamp":1779933152802,"version":"3.53.1"},"reference-count":93,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.4158\/ep-2017-0057","type":"journal-article","created":{"date-parts":[[2017,11,16]],"date-time":"2017-11-16T15:23:43Z","timestamp":1510845823000},"page":"78-90","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"title":["Pheochromocytoma: A Genetic And Diagnostic Update"],"prefix":"10.1016","volume":"24","author":[{"given":"Leilani B.","family":"Mercado-Asis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine I.","family":"Wolf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivana","family":"Jochmanova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Ta\u00efeb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.4158\/EP-2017-0057_bb0010","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.currproblcancer.2014.01.001","article-title":"Pheochromocytoma and paraganglioma: diagnosis, genetics, management, and treatment","volume":"38","author":"Martucci","year":"2014","journal-title":"Curr Probl Cancer"},{"key":"10.4158\/EP-2017-0057_bb0015","first-page":"821","article-title":"Genetic aspects of pheochromocytoma","volume":"21","author":"Kolackov","year":"2012","journal-title":"Adv Clin Exp Med"},{"key":"10.4158\/EP-2017-0057_bb0020","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S0140-6736(05)67139-5","article-title":"Phaeochromocytoma","volume":"366","author":"Lenders","year":"2005","journal-title":"Lancet"},{"key":"10.4158\/EP-2017-0057_bb0025","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.ando.2009.02.008","article-title":"Biochemical diagnosis of pheochromocytoma and paraganglioma","volume":"70","author":"Lenders","year":"2009","journal-title":"Ann Endocrinol (Paris)"},{"key":"10.4158\/EP-2017-0057_bb0030","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/j.beem.2010.10.002","article-title":"Phaeochromocytomas and functional paragangliomas: clinical management","volume":"24","author":"Plouin","year":"2010","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"10.4158\/EP-2017-0057_bb0035","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s40200-016-0226-x","article-title":"Does this patient have pheochromocytoma? A systematic review of clinical signs and symptoms","volume":"15","author":"Pourian","year":"2016","journal-title":"J Diabetes Metab Disord"},{"key":"10.4158\/EP-2017-0057_bb0040","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1093\/omcr\/omv058","article-title":"A vicious cycle of acute catecholamine cardiomyopathy and circulatory collapse secondary to pheochromocytoma","volume":"2015","author":"Otusanya","year":"2015","journal-title":"Oxf Med Case Reports"},{"key":"10.4158\/EP-2017-0057_bb0045","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1055\/s-0032-1306294","article-title":"High incidence of cardiovascular complications in pheochromocytoma","volume":"44","author":"Zelinka","year":"2012","journal-title":"Horm Metab Res"},{"key":"10.4158\/EP-2017-0057_bb0050","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1016\/j.jacc.2016.03.543","article-title":"Pheochromocytoma Is Characterized by Catecholamine-Mediated Myocarditis, Focal and Diffuse Myocardial Fibrosis, and Myocardial Dysfunction","volume":"67","author":"Ferreira","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.4158\/EP-2017-0057_bb0055","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1161\/CIRCULATIONAHA.113.002762","article-title":"Catecholamine-induced myocarditis in pheochromocytoma","volume":"129","author":"de Miguel","year":"2014","journal-title":"Circulation"},{"key":"10.4158\/EP-2017-0057_bb0060","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1056\/NEJMoa020152","article-title":"Germ-line mutations in nonsyndromic pheochromocytoma","volume":"346","author":"Neumann","year":"2002","journal-title":"N Engl J Med"},{"key":"10.4158\/EP-2017-0057_bb0065","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1055\/s-0031-1301302","article-title":"An Update on the Genetics of Paraganglioma, Pheochromocytoma, and Associated Hereditary Syndromes","volume":"44","author":"Gimenez-Roqueplo","year":"2012","journal-title":"Horm Metab Res"},{"key":"10.4158\/EP-2017-0057_bb0070","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1097\/CCO.0000000000000249","article-title":"Pheochromocytoma and paraganglioma: molecular testing and personalized medicine","volume":"28","author":"Burnichon","year":"2016","journal-title":"Curr Opin Oncol"},{"key":"10.4158\/EP-2017-0057_bb0075","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1007\/s12022-011-9189-0","article-title":"Rationale for anti-angiogenic therapy in pheochromocytoma and paraganglioma","volume":"23","author":"Favier","year":"2012","journal-title":"Endocr Pathol"},{"key":"10.4158\/EP-2017-0057_bb0080","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1056\/NEJMoa1205119","article-title":"Somatic HIF2A gain-of-function mutations in paraganglioma with polycythemia","volume":"367","author":"Zhuang","year":"2012","journal-title":"N Engl J Med"},{"key":"10.4158\/EP-2017-0057_bb0085","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1200\/JCO.2012.47.1912","article-title":"New syndrome of paraganglioma and somatostatinoma associated with polycythemia","volume":"31","author":"Pacak","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.4158\/EP-2017-0057_bb0090","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s00109-014-1205-7","article-title":"Germ-line PHD1 and PHD2 mutations detected in patients with pheochromocytoma\/paraganglioma-polycythemia","volume":"93","author":"Yang","year":"2015","journal-title":"J Mol Med (Berl)"},{"key":"10.4158\/EP-2017-0057_bb0095","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1093\/jnci\/djt201","article-title":"Hypoxia-inducible factor signaling in pheochromocytoma: turning the rudder in the right direction","volume":"105","author":"Jochmanov\u00e1","year":"2013","journal-title":"J Natl Cancer Inst"},{"key":"10.4158\/EP-2017-0057_bb0100","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.critrevonc.2016.01.022","article-title":"Updates on the genetics and the clinical impacts on phaeochromocytoma and paraganglioma in the new era","volume":"100","author":"Pillai","year":"2016","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.4158\/EP-2017-0057_bb0105","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1007\/s00109-012-0967-z","article-title":"A novel EPAS1\/HIF2A germline mutation in a congenital polycythemia with paraganglioma","volume":"91","author":"Lorenzo","year":"2013","journal-title":"J Mol Med (Berl)"},{"key":"10.4158\/EP-2017-0057_bb0110","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.1056\/NEJMoa0806277","article-title":"PHD2 mutation and congenital erythrocytosis with paraganglioma","volume":"359","author":"Ladroue","year":"2008","journal-title":"N Engl J Med"},{"key":"10.4158\/EP-2017-0057_bb0115","doi-asserted-by":"crossref","first-page":"E1352","DOI":"10.1210\/jc.2013-4375","article-title":"Rare germline mutations identified by targeted next-generation sequencing of susceptibility genes in pheochromocytoma and paraganglioma","volume":"99","author":"Welander","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP-2017-0057_bb0120","doi-asserted-by":"crossref","first-page":"6140","DOI":"10.1038\/ncomms7140","article-title":"Whole-exome sequencing identifies somatic ATRX mutations in pheochromocytomas and paragangliomas","volume":"6","author":"Fishbein","year":"2015","journal-title":"Nat Commun"},{"key":"10.4158\/EP-2017-0057_bb0125","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1158\/1078-0432.CCR-15-1841","article-title":"Recurrent Mutations of Chromatin-Remodeling Genes and Kinase Receptors in Pheochromocytomas and Paragangliomas","volume":"22","author":"Toledo","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.4158\/EP-2017-0057_bb0130","doi-asserted-by":"crossref","first-page":"3","DOI":"10.4161\/epi.23271","article-title":"ATRX: the case of a peculiar chromatin remodeler","volume":"8","author":"Ratnakumar","year":"2013","journal-title":"Epigenetics"},{"key":"10.4158\/EP-2017-0057_bb0135","doi-asserted-by":"crossref","first-page":"e1002772","DOI":"10.1371\/journal.pgen.1002772","article-title":"Loss of ATRX, genome instability, and an altered DNA damage response are hallmarks of the alternative lengthening of telomeres pathway","volume":"8","author":"Lovejoy","year":"2012","journal-title":"PLoS Genet"},{"key":"10.4158\/EP-2017-0057_bb0140","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ccell.2017.01.001","article-title":"Comprehensive Molecular Characterization of Pheochromocytoma and Paraganglioma","volume":"31","author":"Fishbein","year":"2017","journal-title":"Cancer Cell"},{"key":"10.4158\/EP-2017-0057_bb0145","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1210\/jc.2014-1498","article-title":"Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline","volume":"99","author":"Lenders","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP-2017-0057_bb0150","doi-asserted-by":"crossref","first-page":"152","DOI":"10.3803\/EnM.2017.32.2.152","article-title":"Update on Modern Management of Pheochromocytoma and Paraganglioma","volume":"32","author":"Lenders","year":"2017","journal-title":"Endocrinol Metab (Seoul)"},{"key":"10.4158\/EP-2017-0057_bb0155","series-title":"Adrenal Disorders: Physiology, Pathophysiology and Treatment","article-title":"Pheochromocytoma\/paraganglioma: update on diagnosis and management","author":"Jochmanova","year":"2018"},{"key":"10.4158\/EP-2017-0057_bb0160","doi-asserted-by":"crossref","first-page":"5001","DOI":"10.1158\/1078-0432.CCR-16-0606","article-title":"Pheochromoctyoma: The First Metabolic Endocrine Cancer","volume":"22","author":"Jochmanova","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.4158\/EP-2017-0057_bb0165","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1530\/ERC-13-0232","article-title":"Metabolomic profile of the adrenal gland: from physiology to pathological conditions","volume":"20","author":"Imperiale","year":"2013","journal-title":"Endocr Relat Cancer"},{"key":"10.4158\/EP-2017-0057_bb0170","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1210\/en.2013-1549","article-title":"Succinate-to-fumarate ratio as a new metabolic marker to detect the presence of SDHB\/D-related paraganglioma: initial experimental and ex vivo findings","volume":"155","author":"Lendvai","year":"2014","journal-title":"Endocrinology"},{"key":"10.4158\/EP-2017-0057_bb0175","doi-asserted-by":"crossref","first-page":"3903","DOI":"10.1210\/jc.2014-2151","article-title":"Krebs cycle metabolite profiling for identification and stratification of pheochromocytomas\/paragangliomas due to succinate dehydrogenase deficiency","volume":"99","author":"Richter","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP-2017-0057_bb0180","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.neo.2014.10.010","article-title":"Metabolome profiling by HRMAS NMR spectroscopy of pheochromocytomas and paragangliomas detects SDH deficiency: clinical and pathophysiological implications","volume":"17","author":"Imperiale","year":"2015","journal-title":"Neoplasia"},{"key":"10.4158\/EP-2017-0057_bb0185","doi-asserted-by":"crossref","first-page":"3664","DOI":"10.1172\/JCI67230","article-title":"HIF-1 mediates metabolic responses to intratu-moral hypoxia and oncogenic mutations","volume":"123","author":"Semenza","year":"2013","journal-title":"J Clin Invest"},{"key":"10.4158\/EP-2017-0057_bb0190","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1016\/j.ejca.2011.07.016","article-title":"Plasma methoxytyramine: a novel biomarker of metastatic pheochromocytoma and paraganglioma in relation to established risk factors of tumour size, location and SDHB mutation status","volume":"48","author":"Eisenhofer","year":"2012","journal-title":"Eur J Cancer"},{"key":"10.4158\/EP-2017-0057_bb0195","doi-asserted-by":"crossref","first-page":"640","DOI":"10.3390\/metabo4030640","article-title":"The Succinated Proteome of FH-Mutant Tumours","volume":"4","author":"Yang","year":"2014","journal-title":"Metabolites"},{"key":"10.4158\/EP-2017-0057_bb0200","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/mas.21382","article-title":"The succinated proteome","volume":"33","author":"Merkley","year":"2014","journal-title":"Mass Spectrom Rev"},{"key":"10.4158\/EP-2017-0057_bb0205","doi-asserted-by":"crossref","first-page":"6001","DOI":"10.1038\/ncomms7001","article-title":"Fumarate induces redox-dependent senescence by modifying glutathione metabolism","volume":"6","author":"Zheng","year":"2015","journal-title":"Nat Commun"},{"key":"10.4158\/EP-2017-0057_bb0210","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.ccr.2013.04.018","article-title":"SDH mutations establish a hypermethylator phenotype in paraganglioma","volume":"23","author":"Letouze","year":"2013","journal-title":"Cancer Cell"},{"key":"10.4158\/EP-2017-0057_bb0215","doi-asserted-by":"crossref","first-page":"2440","DOI":"10.1093\/hmg\/ddt639","article-title":"Germline mutations in FH confer predisposition to malignant pheochromocytomas and paragangliomas","volume":"23","author":"Castro-Vega","year":"2014","journal-title":"Hum Mol Genet"},{"issue":"Pt A","key":"10.4158\/EP-2017-0057_bb0220","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.mito.2014.08.007","article-title":"Mitochondrial substrates in cancer: drivers or passengers?","volume":"19","author":"Kruspig","year":"2014","journal-title":"Mitochondrion"},{"key":"10.4158\/EP-2017-0057_bb0225","doi-asserted-by":"crossref","first-page":"3787","DOI":"10.1158\/1078-0432.CCR-12-3922","article-title":"Genotype-specific abnormalities in mitochondrial function associate with distinct profiles of energy metabolism and catecholamine content in pheochromocytoma and paraganglioma","volume":"19","author":"Rao","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.4158\/EP-2017-0057_bb0230","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1038\/ncpendmet0615","article-title":"An assessment of biochemical tests for the diagnosis of pheochromocytoma","volume":"3","author":"Pacak","year":"2007","journal-title":"Nat Clin Pract Endocrinol Metab"},{"key":"10.4158\/EP-2017-0057_bb0235","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1111\/cen.12327","article-title":"Biochemical diagnosis of phaeochromocytoma using plasma-free normetanephrine, metanephrine and methoxytyramine: importance of supine sampling under fasting conditions","volume":"80","author":"Darr","year":"2014","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.4158\/EP-2017-0057_bb0240","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1258\/acb.2012.012066","article-title":"Reference intervals for plasma free metanephrines with an age adjustment for normetanephrine for optimized laboratory testing of phaeochromocytoma","volume":"50","author":"Eisenhofer","year":"2013","journal-title":"Ann Clin Biochem"},{"key":"10.4158\/EP-2017-0057_bb0245","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1056\/NEJMc1101502","article-title":"Drugs and pheochromocytoma--don't be fooled by every elevated metanephrine","volume":"364","author":"Neary","year":"2011","journal-title":"N Engl J Med"},{"key":"10.4158\/EP-2017-0057_bb0250","doi-asserted-by":"crossref","first-page":"2656","DOI":"10.1210\/jc.2002-030005","article-title":"Biochemical diagnosis of pheochromocytoma: how to distinguish true- from false-positive test results","volume":"88","author":"Eisenhofer","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP-2017-0057_bb0255","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1210\/jc.2012-3418","article-title":"Unilateral and bilateral adrenalectomy for pheochromocytoma requires adjustment of urinary and plasma metanephrine reference ranges","volume":"98","author":"Osinga","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP-2017-0057_bb0260","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1210\/jc.2004-2025","article-title":"Biochemical and clinical manifestations of dopamine-producing paragangliomas: utility of plasma methoxytyramine","volume":"90","author":"Eisenhofer","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP-2017-0057_bb0265","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1373\/clinchem.2010.153320","article-title":"Measurements of plasma methoxytyramine, normetanephrine, and metanephrine as discriminators of different hereditary forms of pheochromocytoma","volume":"57","author":"Eisenhofer","year":"2011","journal-title":"Clin Chem"},{"key":"10.4158\/EP-2017-0057_bb0270","series-title":"Management of Adrenal Masses in Children and Adults","first-page":"277","article-title":"Management of locally advanced and metastatic pheochromocytoma and paraganglioma","author":"Roman-Gonzalez","year":"2017"},{"key":"10.4158\/EP-2017-0057_bb0275","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1530\/EJE-06-0712","article-title":"The role of 6-[18F] fluorodopamine positron emission tomography in the localization of adrenal pheochromocytoma associated with von Hippel-Lindau syndrome","volume":"156","author":"Kaji","year":"2007","journal-title":"Eur J Endocrinol"},{"key":"10.4158\/EP-2017-0057_bb0280","series-title":"Nuclear Medicine Annual 1995","first-page":"242","article-title":"Somatostatin receptor scintigraphy","author":"Krenning","year":"1995"},{"key":"10.4158\/EP-2017-0057_bb0285","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s11102-006-0270-5","article-title":"Somatostatin receptor imaging for neuroendocrine tumors","volume":"9","author":"de Herder","year":"2006","journal-title":"Pituitary"},{"key":"10.4158\/EP-2017-0057_bb0290","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1530\/ERC-10-0175","article-title":"Expression of somatostatin receptors, dopamine D(2) receptors, noradrenaline transporters, and vesicular monoamine transporters in 52 pheochromocytomas and paragangliomas","volume":"18","author":"Saveanu","year":"2011","journal-title":"Endocr Relat Cancer"},{"key":"10.4158\/EP-2017-0057_bb0295","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/j.1754-9485.2011.02327.x","article-title":"High management impact of Ga-68 DOTATATE (GaTate) PET\/CT for imaging neuroendocrine and other somatostatin expressing tumours","volume":"56","author":"Hofman","year":"2012","journal-title":"J Med Imaging Radiat Oncol"},{"key":"10.4158\/EP-2017-0057_bb0300","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1111\/j.1365-2265.2008.03257.x","article-title":"The role of 18F-FDOPA and 18F-FDG-PET in the management of malignant and multifocal phaeochromocytomas","volume":"69","author":"Ta\u00efeb","year":"2008","journal-title":"Clin Endocrinol"},{"key":"10.4158\/EP-2017-0057_bb0305","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1111\/cen.12126","article-title":"Functional characterization of nonmetastatic paraganglioma and pheochromocytoma by (18) F-FDOPA PET: focus on missed lesions","volume":"79","author":"Gabriel","year":"2013","journal-title":"Clinical Endocrinol (Oxf)"},{"key":"10.4158\/EP-2017-0057_bb0310","doi-asserted-by":"crossref","first-page":"513","DOI":"10.2967\/jnumed.108.058396","article-title":"18F-FDOPA PET and PET\/CT accurately localize pheochromocytomas","volume":"50","author":"Imani","year":"2009","journal-title":"J Nucl Med"},{"key":"10.4158\/EP-2017-0057_bb0315","doi-asserted-by":"crossref","first-page":"3888","DOI":"10.1158\/1078-0432.CCR-14-2751","article-title":"Superiority of [68Ga]-DOTATATE PET\/CT to Other Functional Imaging Modalities in the Localization of SDHB-Associated Metastatic Pheochromocytoma and Paraganglioma","volume":"21","author":"Janssen","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.4158\/EP-2017-0057_bb0320","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s13139-015-0331-7","article-title":"Diagnostic Performance of (68)Ga-DOTATATE PET\/CT, (18)F-FDG PET\/CT and (131) I-MIBG Scintigraphy in Mapping Metastatic Pheochromocytoma and Paraganglioma","volume":"49","author":"Tan","year":"2015","journal-title":"Nucl Med Mol Imaging"},{"key":"10.4158\/EP-2017-0057_bb0325","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1007\/s00259-012-2119-7","article-title":"A comparison of the performance of 68Ga-DOTATATE PET\/CT and 123I-MIBG SPECT in the diagnosis and follow-up of phaeochromocytoma and paraganglioma","volume":"39","author":"Maurice","year":"2012","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.4158\/EP-2017-0057_bb0330","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1007\/s00259-015-3268-2","article-title":"Prospective comparison of (68)Ga-DOTATATE and (18)F-FDOPA PET\/CT in patients with various pheochromocytomas and paragangliomas with emphasis on sporadic cases","volume":"43","author":"Archier","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.4158\/EP-2017-0057_bb0335","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1007\/s00259-013-2548-y","article-title":"A retrospective comparison between 68Ga-DOTA-TOC PET\/CT and 18F-DOPA PET\/CT in patients with extra-adrenal paraganglioma","volume":"40","author":"Kroiss","year":"2013","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.4158\/EP-2017-0057_bb0340","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1007\/s00259-016-3357-x","article-title":"PET\/CT comparing (68) Ga-DOTATATE and other radiopharmaceuticals and in comparison with CT\/MRI for the localization of sporadic metastatic pheochromocytoma and paraganglioma","volume":"43","author":"Janssen","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.4158\/EP-2017-0057_bb0345","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1530\/ERC-16-0231","article-title":"Novel insights into the polycythemia-paraganglioma-somatostatinoma syndrome","volume":"23","author":"D\u00e4rr","year":"2016","journal-title":"Endocr Relat Cancer"},{"key":"10.4158\/EP-2017-0057_bb0350","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1093\/jnci\/djs188","article-title":"Staging and Functional Characterization of Pheochromocytoma and Paraganglioma by 18F-Fluorodeoxyglucose (18F-FDG) Positron Emission Tomography","volume":"104","author":"Timmers","year":"2012","journal-title":"J Natl Cancer Inst"},{"key":"10.4158\/EP-2017-0057_bb0355","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1210\/jc.2014-1048","article-title":"Renaissance of (18)F-FDG positron emission tomography in the imaging of pheochromocytoma\/paraganglioma","volume":"99","author":"Ta\u00efeb","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP-2017-0057_bb0360","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1007\/s00259-012-2215-8","article-title":"EANM 2012 guidelines for radionuclide imaging of phaeochromocytoma and paraganglioma","volume":"39","author":"Ta\u00efeb","year":"2012","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.4158\/EP-2017-0057_bb0365","doi-asserted-by":"crossref","first-page":"E1006","DOI":"10.1152\/ajpendo.00156.2012","article-title":"Sunitinib inhibits catecholamine synthesis and secretion in pheochromocytoma tumor cells by blocking VEGF receptor 2 via PLC-g-related pathways","volume":"303","author":"Aita","year":"2012","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.4158\/EP-2017-0057_bb0370","doi-asserted-by":"crossref","first-page":"E615","DOI":"10.1152\/ajpendo.00035.2011","article-title":"Sunitinib induces apoptosis in pheochromocytoma tumor cells by inhibiting VEGFR2\/Akt\/mTOR\/S6K1 pathways through modulation of Bcl-2 and BAD","volume":"302","author":"Saito","year":"2012","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.4158\/EP-2017-0057_bb0375","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1210\/jc.2008-1836","article-title":"Rationale and evidence for sunitinib in the treatment of malignant paraganglioma\/pheochromocytoma","volume":"94","author":"Joshua","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP-2017-0057_bb0380","doi-asserted-by":"crossref","first-page":"4040","DOI":"10.1210\/jc.2012-2356","article-title":"Treatment with sunitinib for patients with progressive metastatic pheochromocytomas and sympathetic paragangliomas","volume":"97","author":"Ayala-Ramirez","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP-2017-0057_bb0385","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1210\/jc.2008-1972","article-title":"Use of the tyrosine kinase inhibitor sunitinib in a patient with von Hippel-Lindau disease: targeting angiogenic factors in pheochromocytoma and other von Hippel-Lindau disease-related tumors","volume":"94","author":"Jimenez","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP-2017-0057_bb0390","doi-asserted-by":"crossref","first-page":"6162","DOI":"10.1002\/cncr.27675","article-title":"Phase 2 study of everolimus monotherapy in patients with nonfunctioning neuroendocrine tumors or pheochromocytomas\/paragangliomas","volume":"118","author":"Oh","year":"2012","journal-title":"Cancer"},{"key":"10.4158\/EP-2017-0057_bb0395","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1055\/s-0029-1220687","article-title":"Novel and evolving therapies in the treatment of malignant phaeochromocytoma: experience with the mTOR inhibitor everolimus (RAD001)","volume":"41","author":"Druce","year":"2009","journal-title":"Horm Metab Res"},{"key":"10.4158\/EP-2017-0057_bb0400","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1530\/JME-12-0028","article-title":"Combined blockade of signalling pathways shows marked anti-tumour potential in phaeochromocytoma cell lines","volume":"49","author":"N\u00f6lting","year":"2012","journal-title":"J Mol Endocrinol"},{"key":"10.4158\/EP-2017-0057_bb0405","doi-asserted-by":"crossref","first-page":"e87807","DOI":"10.1371\/journal.pone.0087807","article-title":"Cytocidal activities of topoisomerase 1 inhibitors and 5-azacytidine against pheochromocytoma\/paraganglioma cells in primary human tumor cultures and mouse cell lines","volume":"9","author":"Powers","year":"2014","journal-title":"PloS One"},{"key":"10.4158\/EP-2017-0057_bb0410","doi-asserted-by":"crossref","first-page":"4094","DOI":"10.1210\/en.2015-1476","article-title":"Inhibitory Effect of the Noncamptothecin Topoisomerase I Inhibitor LMP-400 on Female Mice Models and Human Pheochromocytoma Cells","volume":"156","author":"Schovanek","year":"2015","journal-title":"Endocrinology"},{"key":"10.4158\/EP-2017-0057_bb0415","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s12672-015-0231-4","article-title":"Pheochromocytoma: Gasping for Air","volume":"6","author":"Jochmanov\u00e1","year":"2015","journal-title":"Horm Cancer"},{"key":"10.4158\/EP-2017-0057_bb0420","doi-asserted-by":"crossref","first-page":"4363","DOI":"10.1016\/j.bmcl.2015.08.087","article-title":"Progress in the development of fatty acid synthase inhibitors as anticancer targets","volume":"25","author":"Mullen","year":"2015","journal-title":"Bioorg Med Chem Lett"},{"key":"10.4158\/EP-2017-0057_bb0425","doi-asserted-by":"crossref","first-page":"R239","DOI":"10.1530\/ERC-16-0542","article-title":"Molecular targeted therapies in adrenal, pituitary and parathyroid malignancies","volume":"24","author":"Angelousi","year":"2017","journal-title":"Endocr Relat Cancer"},{"key":"10.4158\/EP-2017-0057_bb0430","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nrendo.2014.188","article-title":"Paraganglioma and phaeochromocytoma: from genetics to personalized medicine","volume":"11","author":"Favier","year":"2015","journal-title":"Nat Rev Endocrinol"},{"key":"10.4158\/EP-2017-0057_bb0435","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/cen.12341","article-title":"(131)I-MIBG therapy for malignant paraganglioma and phaeochromocytoma: systematic review and meta-analysis","volume":"80","author":"van Hulsteijn","year":"2014","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.4158\/EP-2017-0057_bb0440","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1053\/j.semnuclmed.2016.01.011","article-title":"I-131 Metaiodobenzylguanidine Therapy of Pheochromocytoma and Paraganglioma","volume":"46","author":"Carrasquillo","year":"2016","journal-title":"Semin Nucl Med"},{"key":"10.4158\/EP-2017-0057_bb0445","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1007\/s00259-015-3029-2","article-title":"Peptide receptor radionuclide therapy with (90)Y\/(177)Lu-labelled peptides for inoperable head and neck paragangliomas (glomus tumours)","volume":"42","author":"Puranik","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.4158\/EP-2017-0057_bb0450","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1097\/MPA.0000000000000113","article-title":"Peptide receptor radionuclide therapy with 177Lu-DOTATATE for patients with somatostatin receptor-expressing neuroendocrine tumors: the first US phase 2 experience","volume":"43","author":"Delpassand","year":"2014","journal-title":"Pancreas"},{"key":"10.4158\/EP-2017-0057_bb0455","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s12032-016-0737-9","article-title":"Peptide receptor radionuclide therapy for metastatic paragangliomas","volume":"33","author":"Pinato","year":"2016","journal-title":"Med Oncol"},{"key":"10.4158\/EP-2017-0057_bb0460","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1055\/s-0032-1311637","article-title":"Peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE in individuals with neck or mediastinal paraganglioma (PGL)","volume":"44","author":"Zovato","year":"2012","journal-title":"Horm Metab Res"},{"key":"10.4158\/EP-2017-0057_bb0465","first-page":"629","article-title":"NETTER-1 Phase III in Patients with Midgut Neuroendocrine Tumors Treated with 177Lu-Dotatate: Efficacy and Safety Results","volume":"57","author":"Strosberg","year":"2016","journal-title":"J Nucl Med"},{"key":"10.4158\/EP-2017-0057_bb0470","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/jhh.2012.20","article-title":"An update on the genetics of pheochromocytoma","volume":"27","author":"Karasek","year":"2013","journal-title":"J Hum Hypertens"}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X20393459?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X20393459?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T22:05:39Z","timestamp":1761516339000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X20393459"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":93,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["S1530891X20393459"],"URL":"https:\/\/doi.org\/10.4158\/ep-2017-0057","relation":{},"ISSN":["1530-891X"],"issn-type":[{"value":"1530-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pheochromocytoma: A Genetic And Diagnostic Update","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.4158\/EP-2017-0057","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}